Managing Director at IPQ Analytics, LLC and Strategic Medicine, Inc.
Michael N. Liebman, Ph.D (theoretical chemistry and protein crystallography) is the Managing Director of IPQ Analytics, LLC and Strategic Medicine, Inc after serving as the Executive Director of the Windber Research Institute (now Chan Soon-Shiong Institute for Molecular Medicine) from 2003-2007. He is an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University and also Fudan University. Previously, he was Director, Computational Biology and Biomedical Informatics, University of Pennsylvania Cancer Center 2000-2003. He served as Global Head of Computational Genomics, Roche Pharmaceuticals and Director, Bioinformatics and Pharmacogenomics, Wyeth Pharmaceuticals, Director of Genomics for Vysis, Inc. He is a co-founder of Prosanos, Inc (now United BioSource) (2000). He was Associate Professor of. Pharmacology and of Physiology/Biophysics at Mount Sinai School of Medicine. He serves on 14 scientific advisory boards and the Board of Directors of the Nathaniel Adamczyk Foundation in Pediatric ARDS and Innovene Pharmaceuticals. Michael is Chair of the Informatics Program and also Chair of Translational Medicine and Therapeutics for the PhRMA Foundation and a member of their Scientific Advisory Board. He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics, for Clinico-Economics and Outcomes Research and Biomedicine Hub, and the International Park for Translational Biomedicine (Shanghai). He is a member of the IUPAC Division on Human Health’s Medicinal Chemistry subcommittee. He has served on the External Advisory Board for the INBRE (NIH) program for the state of Delaware since 2000. He is an Invited Professor at the Shanghai Center for Bioinformatics Technology and of the Chinese Academy of Sciences. His research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective. He utilizes systems-based approaches and design thinking to represent and analyze risk/benefit analysis in pharmaceutical development and healthcare.
Track: Decision and Risk Analysis
Tuesday, April 16, 11:30am–12:20pm
Precision Medicine vs Accurate Medicine? A Critical Decision Fraught With Risk
While scientists can rigorously define the terms accuracy and precision, in healthcare they are used colloquially, and this affects us personally through clinical decisions that involve friends, family and ourselves. To appropriately use these concepts to guide critical risk management and decision making we must consider the diverse perspectives and priorities of patients, physicians, payers, pharma and regulators. We develop comprehensive models of this complexity that can be objectively applied to any disease, implement the model in a “learning environment” and then use it to identify, prioritize and quantify elements of risk to improve personal and system-based decision making. We utilize a broad range of analytical tools,e.g.,graph theory, stochastic modeling, signal processing, etc., which we apply as appropriate to the specific question that needs to be addressed, and data that is available, across multiple scales. This approach should be transferable to the analysis of other complex networks and system-level problem areas.